US FDA issues EIR with VAI classification for Pithampur (SEZ) facility

Symbiotec has received the Establishment Inspection Report (EIR) from the U.S. FDA for its Pithampur (SEZ), Madhya Pradesh plant, classified as Voluntary Action Indicated (VAI).

Tue 29 Sep 2026

Inspection Period

August 10, 2026 to August 14, 2026

Facility Location

Pithampur (SEZ), Madhya Pradesh

EIR Classification

Voluntary Action Indicated (VAI)

Regulatory Body

U.S. FDA

What was announced

Symbiotec Pharmalab has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration for its manufacturing facility at Pithampur (SEZ), Madhya Pradesh, with a Voluntary Action Indicated (VAI) status.

The inspection

• Conducted at the Pithampur facility from August 10, 2026 to August 14, 2026.
• The EIR is the formal report the U.S. FDA issues after completing an inspection.

What VAI means

• VAI means the inspectors noted some objectionable conditions or practices, but the agency is not recommending or taking regulatory action.
• Any corrective steps are left to the company on a voluntary basis.
• Receipt of the EIR indicates the inspection has been formally closed out.

Why it matters

U.S. FDA clearance status of a plant affects a company's ability to supply products to the United States market. A VAI outcome is generally viewed as a favourable close-out compared with an Official Action Indicated (OAI) classification, which can lead to restrictions such as warning letters or import alerts.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.